AAI Newsletter

IMMUNOLOGY 2014

PROGRAM PREVIEW

MARCH/APRIL 2014




Enzymes,
low or high pH

AAI Submits Testimony on the Value of Government Employee Attendance at Scienti c Meetings and Conferences

AAI recently submitted testimony to the Senate Committee on Homeland Security and Governmental Affairs regarding the value of government employee attendance at scienti“c meetings and conferences. The testimony became part of the hearing record for the committee•s January 14, 2014, hearing entitled, •Examining Conference and Travel Spending Across the Federal Government.Ž

Over the last several years, policy changes within the federal government have limited the ability of federal employees to attend meetings and conferences. In May 2012, the White House Of“ce of Management and Budget issued a memorandum, which, among other things, required agencies to reduce their travel budgets by 30 percent (from the “scal year 2010 level) and to maintain this reduced level of spending through “scal year 2016. The U.S. Department of Health and Human Services (HHS), of which the National Institutes of Health is part, responded by giving additional scrutiny to travel requests and implementing a more arduous approval process for travel to meetings where the total expense to HHS is more than $75,000. Congress also acted, requiring agencies to submit annual reports on all government-run conferences that cost the federal government more than $100,000. Legislation pending in Congress seeks to impose further restrictions on federal employee travel.

While AAI understands, as stated in its testimony, that these policy changes •were promulgated in an effort to prevent excessive or unnecessary government spending and to prevent abuses,Ž AAI believes that they •have had an unintended and deleterious effectŽ on scientists and the scienti“c enterprise and •have made government scientists feel cut off from the

The National Institutes of Health (NIH) recently announced a new partnership with 10 biopharmaceutical companies, the U.S. Food and Drug Administration, and eight non-pro“t organizations that will aim •to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets of diseaseŽ (http://www.nih.gov/science/amp/index.htm). This alliance, formally known as the Accelerating Medicines Partnership (AMP), is slated to be a “ve-year collaboration with a total cost of about $230 million. A little more than one-half of that funding will come from NIH.

AMP will focus initially on three disease areas: Alzheimer•s disease, type 2 diabetes, and autoimmune disorders (speci“cally, rheumatoid arthritis and lupus). According to the NIH news release announcing the

E R. U H
AAI L
A A

Emil R. Unanue, M.D., Washington University School of Medicine, is the recipient of the 2014 AAI Lifetime Achievement Award in recognition of a career of extraordinary scienti“c achievement coupled with exceptional leadership and service to AAI. This award is the highest honor bestowed by the AAI Council upon an AAI member.

Dr. Unanue has pioneered fundamental advances in the “eld of antigen processing and presentation, elucidating the biochemical basis of T cell recognition of antigen. His work was the “rst to controvert dogma that macrophages served only to destroy dead cells and pathogens, showing that these cells can actually present antigen to T cells. Unanue also made strides in the “eld to show that proteins need to be processed intracellularly before being recognized by T cells. In 1985, members of his lab published one of the most highly cited, pivotal immunology articles of all time, which demonstrated that major histocompatibility complex (MHC) molecules are able to bind peptides and that these MHC-peptide complexes activate T cells. Unanue•s current work continues to build on these ground-breaking antigen processing and presentation studies in the context of mouse models of autoimmune diabetes and infection.

Unanue has been an AAI member since 1966 and has shown his dedication to serving his fellow AAI members over a span of 30 years. He has served as both associate editor and section editor of as well as member and chair of the editorial board. Unanue has also served as member and chair of the Travel Awards, Publications, and Nominating Committees and as a member of the Education Committee. He has spoken at AAI annual meetings as an AAI Distinguished Lecturer and delivered the Minority Affairs Guest Lecture.

Unanue•s commitment to scienti“c service has been wide-reaching. He has held positions on scienti“c advisory boards for the Lupus Research Institute, Howard Hughes Medical Institute, the National Institute of AllT ce.Te of AllT ce.Tep2ual mLino2to bind peptides and that these (,)spacbEe Tc 0 T(T cell r)20(ecognP[(thewof AllT c the Ncaticmpats8 Ti(dsam)5(er)5(e hasB-8(i.e (,)sple15 ns)10(,)5( )]TJ)]TJ* [(tob37 T 0tJKM)30(30(Gol5(er[(eapusr)60(.)]ectur A) 0(,)nnfa(ser)-

His past trainees laud Paul for his scholarly knowledge, his rigor in evaluating experimental data, and his open-mindedness to new ideas. •He liked ideas and considered those from junior fellows, including ideas that contradicted his own (especially those that contradicted his own), with great respect,Ž says a former fellow, Fred Finkelman, McDonald Professor of Medicine and professor of pediatrics at the University of Cincinnati School of Medicine. •I learned that a hypothesis was an idea to test, not something to prove; that data take precedence over theories, which are usually wrong; and that results have to be reproducible and to make sense.Ž Another past trainee, Anthony DeFranco, professor, Department of Microbiology and Immunology, University of California, San Francisco, expands, recalling when early experiments in the laboratory suggested that B cell activation was MHC-restricted: •I remember his saying, •This experiment may convince reviewers, but does it convince us?• I think that statement fully encapsulates Bill•s view. He wants to get the right answer; publishing papers and being an author isn•t what is important, getting the right answer is what is important. [We] then went back to the drawing board and came up with an experimental setup that Bill now agreed would test the question without leaving uncertainty*ƒ*.When this experiment was done, we convincingly got the opposite answer, which agrees well with understanding 30 years later.Ž

Paul•s past fellows commend his generosity and sel”essness, describing how Paul shifted his own research efforts to give

the team has reported similar antitumor responses in more CLL patients, as well as patients with B cell acute lymphoblastic leukemia. Work is underway to use the same strategy to treat other malignancies. The successful application of CAR T cells to treat cancer has generated much recent excitement and offered new hope to the cancer patient community.

•Dr. June brought several unique things to this work that made it successful,Ž says Kenneth M. Murphy, professor and HHMI investigator, Washington University School of Medicine. •It required Dr. June•s understanding of the detailed signaling properties of T cells and costimulatory pathways in order to engineer into the CAR constructs the appropriate type of signaling properties that made the chimeric receptors work in the proper type and quality of activation. But well beyond this, it took an ever greater (in my opinion) degree of personal dedication to the real application of this to human problems*ƒ* Dr. June took enormous personal effort to organize the clinical translational side, which is far beyond the typical challenge of basic research in immunology.Ž

June earned his M.D. from Baylor College of Medicine in 1979. Following a research fellowship at the World Health Organization, he completed his internship and residency at the National Naval Medical Center and then a fellowship in oncology at the University of Washington and Fred Hutchinson Cancer Research Center. In 1986, he joined the faculty of Uniformed Services University of the Health Sciences, holding the rank of full professor at his departure in 1999. He currently serves as professor of pathology and laboratory medicine and professor of medicine at the University of Pennsylvania, Perelman School of Medicine.

Dr. June is a member of the Institute of Medicine of the National Academy of Sciences and the American Association of

at Dana Farber Cancer Institute to his current positions as Latham Family Professor and professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of medicine and senior investigator of the Program in Cellular and Molecular Medicine at Children•s Hospital Boston. He also holds honorary professorships at several international universities and advises a number of pharmaceutical companies.

Dr. Springer is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. In addition to these honors, he has received NIH MERIT Grant Awards, the Basic Research Prize from the American Heart Association, the Crafoord Prize in Polyarthritis from the Royal Swedish Academy of Sciences, and many other awards. He has served on a number of journal editorial boards, including [illegible] and [illegible] - Springer has also acted as a member of NIH study sections, the Howard Hughes Medical Institute Scienti“c Review Board, a National Research Council Committee, and the Board of Trustees at Children•s Hospital Boston.

An AAI member since 1979, Springer has served as a block symposium chair for the AAI annual meeting, a member of the Nominating Committee, and an associate editor for [illegible]

[illegible]

A. F
R AAI-
BD B
I A

Katherine A. Fitzgerald, Ph.D., University of Massachusetts Medical School, was chosen to receive the 2014 AAI-BD Biosciences Investigator Award. She has made fundamental contributions to our understanding of innate immune signaling and function. This trajectory began with her early discovery of the Toll-like receptor (TLR) adapter molecule known as Mal (or TIRAP), as a fellow in the laboratory of Luke O•Neill at Trinity College Dublin. Upon moving to the University of Massachusetts in 2002, she has expanded her research into new areas and has continued to make high-profile discoveries, first in the laboratory of Douglas Golenbock and then as an independent investigator. These include the discovery of another TLR adapter, TRAM; identification of TBK1 and IKK-epsilon as kinases that phosphorylate and activate the transcription factors IRF3 and IRF7; discovery of the AIM2 inflammasome and its role in recognition of microbial DNA; and demonstration that TRIF-dependent signaling by TLR4 licenses NLRP3 inflammasome activation by Gram-negative bacteria. In addition, recent studies in the Fitzgerald laboratory have provided new evidence for the importance of regulatory long-coding RNAs

identind [(he, as ontr)-ue supe arL.
Ld
University of Massachusetts Medic [(Scho0( )]TJlleg)20(egu20(egdepend

edal

Awaronin
L T Jlo



Members in the News

W H A AAI P C

The Emergence of Immunology in Pittsburgh

by Bryan Peery and John Emrich

IMMUNOLOGY 2014 [illegible] AAI [illegible]

Pittsburgh, a major center for immunological research, began its steep ascent to that acclaim just 60 years ago when it attracted a few ambitious, young immunologists to the University of Pittsburgh (Pitt). Among the scientists who arrived in the late 1940s and 1950s were several distinguished members of the American Association of Immunologists (AAI), including Jonas Salk (AAI '47), Frank Dixon (AAI '50, president 1971–72), F. Sargent Cheever (AAI '50, president 1963–64), and Niels Jerne (AAI '65). We chronicle below the achievements of these and other leading immunologists and their roles in shaping the history of immunology in Pittsburgh.

Pittsburgh Municipal Hospital, 1939

[illegible]

E M R P

The discovery of large coal veins in 1833 brought rapid industrialization to Pittsburgh. The transformation of Pittsburgh from a small frontier city to an industrial center was accelerated by the mass production of steel and the heightened demand for that product during the American Civil War.

The city's prominence in higher education and medicine, however, experienced a slower emergence. Western University of Pittsburgh was incorporated in 1819,[1] but lacked a sizable enrollment until the turn of the twentieth century. It was not until 1853, following a decade that witnessed endemic typhoid and tuberculosis, as well as multiple outbreaks of smallpox and cholera, that the first chartered public hospital, Western Pennsylvania Hospital, opened its doors.[2] A group of local physicians chartered the first medical school in 1883, and construction began after 250 shares of stock were sold for $100 each.[3] Western Pennsylvania Medical College opened its doors to the first class in 1886. Initially, the college was completely autonomous, but in 1892, it entered into a formal relationship with Western University, of ¿cially becoming the Medical Department of Western University, although it was the stockholders, not the university, who had ownership and authority over the department.

Western University underwent dramatic changes in 1908 to raise both the standards and prominence of the school. A new name—the University of Pittsburgh—was adopted, the campus was relocated from its site in Pittsburgh's North Side section to the Oakland area of the city; and the university formally acquired the medical college. With full control of what was now the University of Pittsburgh School of Medicine, the administration of Pitt hired a new chancellor, Samuel McCormick, who, modeling the institution on the top medical schools in the country, began recruiting accomplished researchers for faculty positions and raising the standards for enrollment and graduation. Facilities and opportunities for clinical research followed, as a new medical school building was opened in 1911, and formal relationships were forged with St. Francis and Mercy hospitals in 1912.

The University of Pittsburgh School of Medicine was not the only medical research institution in the city in these years. The William H. Singer Memorial Research Laboratory was founded at Allegheny General Hospital in 1914 as a research laboratory dedicated to the study of medical and surgical problems. Its staff included Oscar M. Teague (AAI '20), a noted bacteriologist and the first active AAI member in Pittsburgh,[4] as well as other researchers, who, although not AAI members, published early articles in The Journal of Immunology (The J. Immunol.).[5] Western Pennsylvania Hospital also attracted talented immunologists

[1] The Pittsburgh Academy was founded in 1787 as a preparatory school and reincorporated as an institution of higher learning by the Commonwealth of Pennsylvania in 1813.

[2] Barbara I. Paull, *A [illegible]* (Pittsburgh: University of Pittsburgh Medical Alumni Association, 1986), 5…6, 26.

[3] Ibid., 11. The price of each share was approximately $2,400 in today•s dollars.

[4] •Oscar Teague,Ž *[illegible] J [illegible]* 9, no. 1 (1924): 1…5.

[5] See, for example, G. R. Lacy and C. C. Hartman, •Speci"c Reactions of the Body Fluids in Pneumococcic Infections,Ž *[illegible] J [illegible]* 3, no. 1 (1918): 43…49.

beginning in the 1910s: Jacques J. Bronfenbrenner (AAI ’20, president 1942–46) was director of research and diagnostic laboratories at Western Penn from 1913 to 1917, and Arthur P. Locke (AAI ’26) and Ralph R. Mellon (AAI ’22) were researchers in the laboratories from the 1930s until the 1950s.

The stature of the medical research in Pittsburgh steadily

was then experimenting with using ultraviolet light to produce killed-virus vaccines.[14] After completing a two-year medical internship at Mount Sinai Hospital in New York, Salk contacted Francis in 1942 about a job. The previous year, Francis had become chair of the Department of Epidemiology at the University of Michigan School of Public Health and director of the [illegible] Commission of the Armed Forces Epidemiological Board. Francis brought Salk to Michigan, helping Salk secure both a National Research Council Fellowship and a draft deferment.[15]

After five years under Francis, Salk grew restless, desiring a promotion and more independence. He and Francis had a cordial relationship, but Francis could offer only an assistant professorship. When McEllroy promised to make Salk an associate professor and head of the Virus Research Laboratory at Pitt in 1947, he immediately accepted the offer.[16]

At the time of Salk's arrival in Pittsburgh, the medical school's transition to major research institution was far from complete. Salk soon realized that it fell upon him to be an impetus for change. He later recalled the shock of learning that most of his colleagues "were part-time instructors who earned their living in private practice and had neither the time nor inclination for basic research."[17] He would have to build his laboratory from the ground up—literally. Starting with two rooms and a technician in the basement of Municipal Hospital, he waged what one colleague recalled as "a kind of guerilla war" for space and funding.[18]

He continued his investigations into influenza virus but increasingly turned to poliomyelitis virus, at least in part because he knew this research would attract funding.[19] When NFIP approached him in late 1947 about doing the tedious technical work of typing poliovirus, Salk readily agreed to do what senior researchers had shunned. In return, he received large research grants, beginning in 1948, to help him build his laboratory.[20] By 1949, his laboratory and offices had expanded to two floors in Municipal Hospital, he had been promoted to full professor, and he was hiring his own research faculty. One of the scientists whom he brought into his laboratory was Julius S. Youngner (AAI '50) from the University of Michigan, who, as a senior assistant research scientist at the National Cancer Institute, had specialized in cell culture techniques. Youngner would remain an active member of the Pitt faculty for the next 50 years.

By 1951, Salk's laboratory had completed its typing project, concluding that there were three distinct types of poliovirus. The lab shifted its efforts to producing a vaccine. Based on the success that his mentor Francis had had with a killed-virus flu vaccine, Salk chose to pursue a killed-poliovirus vaccine over the attenuated-virus vaccine that the majority of other scientists, including his rivals Albert B. Sabin (AAI '46) and Hilary Koprowski (AAI '46), preferred.

Even within the small community of researchers at Pitt, Salk had competition. In 1950, Parran recruited William McDowall Hammon (AAI '46) to chair the Department of Epidemiology and Microbiology at the

polio. Unfortunately, as Hammon himself pointed out, the immunity produced was only temporary, and the gamma-globulin was in short supply.[4]

Meanwhile, Hammon's passive immunization approach was eclipsed by Salk's March 1953 announcement of the successful completion of the

AAI DISTINGUISHED LECTURERS

6.00 6.4

Kristin A. Hogquist

AAI Lifetime Achievement Award Presentation

.00

Chair:
Marc K. Jenkins, University of Minnesota Medical School
AAI President

Award Recipient:
Emil R. Unanue, Washington University School of Medicine

AAI President Marc K. Jenkins will introduce the awardee and present the award prior to the start of the President's Address.

AAI Excellence in Mentoring Award Presentation

0

Chair:
Marc K. Jenkins, University of Minnesota Medical School
AAI President

Award Recipient:
William E. Paul, NIAID, NIH

AAI President Marc K. Jenkins and Anthony L. DeFranco, University of California, San Francisco, will introduce the awardee and present the award prior to the start of the President's Symposium.

AAI-BD Biosciences Investigator Award Presentation and Lecture



MONDAY, MAY 5, 8:00 AM ... 11:30 AM

Major Symposium E: Fueling Immunity: Metabolic Effects in and on the Immune System

Chairs:

Douglas R. Green, St. Jude Children•s Research Hospital

Barbara S. Nikolajczyk, Boston University School of Medicine

Speakers:

Douglas R. Green, St. Jude Children•s Research Hospital

Steven J. Bensinger, University of California, Los Angeles

Erika L. Pearce, Washington University School of Medicine

Barbara S. Nikolajczyk, Boston University School of Medicine

Vishwa Deep Dixit, Yale School of Medicine

Myriam Aouadi, University of Massachusetts Medical School

Major Symposium F: Progress and Challenges in Vaccines for the Major Killers: Malaria, Tuberculosis, and HIV/AIDS

Chairs:

John T. Harty, University of Iowa

JoAnne L. Flynn, University of Pittsburgh School of Medicine

Speakers:

Robert A. Seder, NIAID, NIH

John T. Harty, University of Iowa

[eu6 TfGS2yasIAIIsm]TJ/T1_0 1 Tf-0.0001 Tc 0.0001 Tw [(, U)40(niversity of C)12(ale 236(uT w immunity J/12(ales rF36(uound0001 Tw [(, U)H5tlJ.)



AAI COMMITTEE ON PUBLIC AFFAIRS

Rock Talk-ing With Sally Rockey: The Issues, the Blog, and the Woman Behind It All

SUNDAY, MAY 4, 12:30 PM – 2:00 PM

Chair:

Elizabeth J. Kovacs, Chair, AAI Committee on Public Affairs

Speaker:



Sally Rockey

Deputy Director for Extramural Research and Director, Of"ce of Extramural Research, NIH

So you get the blog, and you read it, and you sometimes even comment. The issues raised are important and thought-provoking, and the questions asked can be provocative. But the person who writes this blog is also a senior leader at NIH who has in"uence over NIH policy, particularly, over many of the key issues that affect you. Who is she and what do you want her to know about you? Come to this session to meet Sally Rockey, to learn about upcoming NIH plans for the extramural research community, and to get answers to the questions you•ve always wanted to ask.

AAI CLINICAL IMMUNOLOGY COMMITTEE

Personalized Medicine from an Immunologist's Perspective

SATURDAY, MAY 3, 3:45 PM – 5:45 PM

Chairs:

Robert L. Modlin, University of California, Los Angeles

Charles A. Dinarello, University of Colorado Denver

The integration of basic research and clinical knowledge has

Careers in Science Roundtable

SUNDAY, MAY 4, 11:30 AM – 1:00 PM

Chair:

Scheherazade Sadegh-Nasseri, Johns Hopkins Medical Institute
Chair, AAI Committee on the Status of Women

Registration Fee: $20 (Lunch included)

At this always popular session, you•ll have the opportunity to meet with scientists at your own career stage and with more experienced scientists to explore speci“c career issues important to men and women in science today. Learn what others are thinking and gain insights into issues you are confronting in your own situation. New topics this year offer insights into NIH Study Sections and considerations for scientists in M.D.-Ph.D. careers. Choose from these and the other vital topics related to the environment you work in (academic research, biotech industry, governmental agencies, non-pro“ts), the transitions from speci“c career stages, or issues in balancing career and family in any career path. Don•t miss this great networking opportunity!

AAI PUBLICATIONS COMMITTEE

Publishing Your Scientific Work: Tips on Writing, Responding to Reviewers, and Avoiding Ethical Pitfalls

SUNDAY, MAY 4, 12:30 PM – 2:00 PM

Chairs:

Eugene M. Oltz, Washington University School of Medicine

Pamela J. Fink, University of Washington School of Medicine
Editor-in-Chief,

Your data may be good and your “ndings may be signi“cant, but your manuscript will navigate peer review more smoothly if you present your “ndings well. What steps can an author take to improve data presentation? What is considered an inappropriate, even unethical, presentation of data? What will make the manuscript easier for the reviewer to read and evaluate? How can the author best respond to reviewers? With ample time for questions and answers at the end of the session, experienced editors will address these and other questions about scienti“c publishing in this session sponsored by the AAI Publications Committee.

Speakers:

Eugene M. Oltz, Washington University School of Medicine

Kristin A. Hogquist, University of Minnesota

Pamela J. Fink, University of Washington School of Medicine
Editor-in-Chief,

AAI VETERINARY IMMUNOLOGY COMMITTEE & AMERICAN ASSOCIATION OF VETERINARY IMMUNOLOGISTS (AAVI) JOINT SYMPOSIUM

Vaccines for the Modern Era: Implications for Human and Animal Health

SATURDAY, MAY 3, 12:30 PM – 2:30 PM

Chairs:

Laurel J. Gershwin, University of California, Davis

Carol G. Chitko-McKown, Genetics, Breeding, and Animal Health Research Unit, ARS, USDA

This symposium will feature topics on both human and veterinary vaccines, with emphasis on new technologies and new information for more appropriate targeting of the immune response to achieve protective immunity. Advances in understanding immune responses to veterinary and human pathogens and applications of that information to vaccine design illustrate a commonality that supports the current •one healthŽ concept in medicine.

Mark K. Slifka, Oregon Health and Science University

Tilahun Yilma, University of California, Davis

Ronald D. Schultz, University of Wisconsin

CENTENNIAL TIMELINE … 3RD FLOOR CORRIDOR

Back by Popular Demand!

Travel the AAI Centennial Timeline spanning the 3rd ”oor corridor. The Centennial Timeline depicts important developments for AAI and immunology, science and technology, and U.S. and world history. Even if you viewed this structure in Hawaii at the AAI meeting, you•ll “nd worlds more to explore in this chronicle of the great legacy informing your work today.

Also on Display:

- Pro“les of AAI Nobel laureates and Lasker Award recipients
- AAI StoryBooth, featuring attendees• favorite immunology career recollections (Record your own while you are there!)

GUEST SOCIETY SYMPOSIA

American Association of Pharmaceutical Scientists (AAPS) Symposium: ***Immunogenicity of Biotherapeutics: Predicting Potential Contributors and Mechanisms***

SUNDAY, MAY 4, 8:00 AM – 10:00 AM

Chairs:

Arunan Kaliyaperumal, Amgen, Inc.

Bonnie Rup, P“zer

Speakers:

Terry Goletz, Amgen, Inc.

Jack Ragheb, FDA

Genhong Cheng, University of California, Los Angeles

Scheherazade Sadegh-Nasseri, Johns Hopkins School of Medicine

IMMUNOLOGY 2014™ GALA

You are invited to attend

An Evening of Discovery!



Canadian Society for Immunology (CSI) Symposium: ***Transcriptional Regulation of Hematopoiesis***

SATURDAY, MAY 3, 10:15 AM – 12:15 PM

Chairs:

Michele K. Anderson, Sunnybrook Research Institute, Toronto

Rodney P. DeKoter, Western University, London, Ontario

Speakers:

R. Keith Humphries, Terry Fox Laboratory, Vancouver

Trang Hoang, IRIC, Montreal

Rodney P. DeKoter, Western University, London, Ontario

Michele K. Anderson, Sunnybrook Research Institute, Toronto

Juan Carlos Zœæiga-P ücker, Sunnybrook Research Institute
Toronto

Chinese Society of Immunology (ChSI) Symposium: ***Cancer Immunotherapy Targeting Chronic Inflammation and Immunosuppression***

SUNDAY, MAY 4, 10:15 AM – 12:15 PM

Chairs:

Xuetao Cao, Chinese Academy of Medical Sciences, Beijing

Olivera J. Finn, ***Cancer Immunothe Sunnybrook Research Institute ion factors in hematcqu Tmgh hoolf-TTf Tc stuteatory, Vancouver***

-1.824 TOJ.vieJ.n"amm3tion2:15i9.5 0 0 10236 356log101 a00(or)6(onto)]TJ /T1_T* [(O)6(liv)1LNDA
, Western UioTorelopment and pr-lingsBlatioIphysiceJ.101 Tc 0.0001 Tw mma0[(,)60(W)6-8(io24.555m)22.4Chielta T-e 9(F)27(inn,)39( )]TJ504 Tw in

-1.824 TMe Sac of Ipan00c40(cTf0.0i9.5 0 0 10236 3500(or)6(onto)]TJ/T1_T*[(O)6(liv)1T)9[(So1.d yaboro111Che()]TJ1.115 -1.294 Td(acute lN1.d a-
Xu424 TD 10:ons4 TDAM _0 1 12:ons01 Tc [(, Chinese A)12(cademy of M)30(edical Sciences)10(, B.71 311.6ng)] /T1_2 1 Tf -0.0104 Tc 0.0004 Tw T*

Japanese Society for Immunology (JSI) Symposium: ***Highlights of Immunology in Japan: JSI Awardees Symposium***

MONDAY, MAY 5, 3:45 PM – 5:45 PM

Chairs:

Ichiro Taniuchi, RIKEN Center for Integrative Medical Sciences

Yasunobu Miyake, Kyushu University

Speakers:

Ichiro Taniuchi, RIKEN Center for Integrative Medical Sciences

Takashi Sekiya, Keio University

Keiji Hirota, Osaka University

Yasunobu Miyake, Kyushu University

Hideyuki Yanai, University of Tokyo

Korean Association of Immunologists (KAI) and Association of Korean Immunologists in America (AKIA) Symposium: ***Regulation of Host Immunity by Immune Cell Receptors and Effectors***

SATURDAY, MAY 3, 3:45 PM – 5:45 PM

Chairs:

Charles D. Surh, Institute for Basic Science, Korea

Mi-La Cho, Catholic University of Korea

Speakers:

Jae U. Jung, University of Southern California

Yong-Soo Bae, Sungkyunkwan University

Sungjin Kim, Michigan State University

Mi-La Cho, Catholic University of Korea

Hyun Park, NCI, NIH

Society for Immunotherapy of Cancer (SITC) Symposium: ***Cancer Immunology and Immunotherapy: From Basic Science to Clinical Application***

MONDAY, MAY 5, 12:30 PM – 2:30 PM

Chairs:

Thomas F. Gajewski, University of Chicago

Lisa H. Butterfield, University of Pittsburgh Cancer Institute

Speakers:

Robert H. Vonderheide, University of Pennsylvania

Nicholas P. Restifo, NCI, NIH

Suzanne L. Topalian, Johns Hopkins University

F. Stephen Hodi, Jr., Dana-Farber Cancer Institute

Society of Mucosal Immunology (SMI) Symposium: ***The Leo Lefrançois Memorial Symposium on T Cell Memory and Protection from Infection***

MONDAY, MAY 5, 10:15 AM – 12:15 PM

Chairs:

Joanne L. Viney, Biogen Idec

Stephen M. Hedrick, University of California, San Diego

Speakers:

David Masopust, University of Minnesota

Vaiva Vezys, University of Minnesota

Kimberly D. Klonowski, University of Georgia

Kamal M. Khanna, University of Connecticut Health Center

Kimberly S. Schluns, University of Texas MD Anderson Cancer Center

Michael J. Bevan, University of Washington

The American Association of Immunologists thanks the following sponsors for their generous support of the 2014 AAI Annual Meeting

Thank you to our Premier Sponsors

PLA I M PO O

ffymetrix

Society for Natural Immunity (SNI) Symposium: *Current Developments in NK Cell Research*

SATURDAY, MAY 3, 12:30 PM – 2:30 PM

Chairs:

Hans-Gustaf Ljunggren, Karolinska Institutet

Chiara Romagnani, German Rheumatism Research Center

Speakers:

Chiara Romagnani, German Rheumatism Research Center

Andrø Veillette, Institut de Recherches Cliniques De Montréal

Yenan T. Bryceson, Karolinska Institutet and University of Bergen

CAREER DEVELOPMENT SESSIONS

Through workshops, roundtables, networking opportunities, and one-on-one counseling, IMMUNOLOGY 2014

Interviewing for a Job

SUNDAY, MAY 4, 10:00 AM – 11:00 AM

Chair:

Mary Litzinger, AAI

Speaker:

Derek Haseltine, Director, Career Services, George Washington University

This session will be focused on tips and techniques to help you successfully navigate the interview process. Emphasis will be on how you can present yourself in the best possible light. You will also learn how to respond to unexpected questions. This session is open to anyone but is especially intended for student and postdoctoral attendees.

2013...2014 AAI PROGRAM COMMITTEE

AAI [illegible] P [illegible] I [illegible]

AAI ABSTRACT PROGRAMMING CHAIRS

AAI [illegible] A [illegible] P [illegible] I [illegible]

Makoto Inoue, Ph.D.
Duke University School of Medicine

Ejaj Intisar
University of Southampton

Jill A. Ippolito
Loyola University, Chicago

Yuval Itan, Ph.D.
Rockefeller University

Sohyun Sophia Jeon
University of Pittsburgh

Hyun-Bae Jie, Ph.D.
University of Pittsburgh

Derek D. Jones, Ph.D.
University of Pennsylvania

Jessica N. Jones, Ph.D.
University of Texas at [illegible] 7056 Tm ( )Tj EMC ET EMC

Ethan George Aguilar
University of California, Davis

Katherine J. Bao
Duke University

Kathleen Bartemes
Mayo Clinic

Ian Belle
Duke University

Yihua Cai, Ph.D.
University of Louisville

Tara Capece, M.P.H.
University of Rochester

Eleanor Clancy-Thompson
Dartmouth College

Elizabeth V. Clarke, M.S., M.P.H.
University of California, Irvine

Sherrie J. Divito, M.D., Ph.D.
Harvard Medical School

Rodney Dixon Dorand, Jr.
Case Western Reserve University

Jarrod A. Dudakov, Ph.D.
Memorial Sloan-Kettering Cancer Center

Akinola O. Emmanuel
University of Chicago

Heather Marie Evans
University of Kentucky

Holly Evans
Uniformed Services University of the
Health Sciences

Kristen Fantetti, Ph.D.
Duquesne University

Rebecca A. Flitter, M.P.H.
University of Pittsburgh

Brian J. Franz
Albany Medical College

Pennsylvania State University

YsonHutett]TJ 0 Tc 8.901 0 Td ( )Tj /T1_2 1 Tf 0.015 Tc -8.901 -1.059 Td (UUniversity of)37(Al74(arexasedical CoBnz chT

Yaoyao Fu
Pennsylvania State University

Yoichi Furuya, Ph.D.
Albany Medical College

Sara Gibson
University of Alabama, Birmingham

Hannah Priyadarshini Gideon, University of Al2atherine J. Bao

Abbott Laboratories, Charlotte M. Vines (AAI •05) from the University of Kansas Medical Center, and Aldo Vaca”ores Salinas (AAI •14), a graduate student at the University of Iowa. In this interactive session, the panelists “elded a range of questions, from the most important criteria in choosing a graduate school to whether joint M.D.…Ph.D. programs are required training for physician scientists. The workshop was followed by a meet-and-greet session for graduate program representatives to provide students with additional information about the “eld and answer questions about their own institutions and programs.

The AIC continued its commitment to career development through its workshop blocks and the AIC John Wallace Diversity Program. The workshop blocks give all presenters the opportunity to speak, providing a valuable training experience for students. The annual Wallace luncheon provides the opportunity for present Wallace scholars to meet one-on-one with AIC councillors, past Wallace scholars, and the National Institute of Allergy and Infectious Diseases representatives to hear about their scienti“c career experiences and receive advice on a range of career issues, including research-funding opportunities.

AAI staff hosted a booth in the exhibit and poster hall. There, Jennifer Woods, membership manager, and Mary Litzinger (AAI •11), manager of educational and career development programs, engaged AIC attendees in discussion about the bene“ts and resources available through AAI.

Next Issue: *AAI P* AAI Newsletter.

AIC Keynote Lecturer Laurie Glimcher and Conference Chair Maria-Luisa Alegre



Virginia Shapiro (far left), Mary Litzinger (fourth from

PRESIDENT•S CIRCLE

Contributions $500 and above

COUNCIL•S CIRCLE

Contributions $250 - $499

CHAIRS• CIRCLE

Contributions $150 - $249

LEADERS• CIRCLE

Contributions $100 - $149

ADVOCATES• CIRCLE

Contributions $50 - $99

CONTRIBUTORS• CIRCLE
Contributions up to $49

Donations to the Lefrançois Memorial Award Fund are acknowledged on p. 64.

GRANT AND AWARD DEADLINES

M 18

A M P

Prize/Award: Up to nine four-year awards to support the postdoctoral research and career development of eligible physicians and dentists; each scholar will receive an annual stipend of up to $75,000 comple - mented by a $30,000 annual grant toward support of research activities

Eligibility: Physicians and dentists from histori- cally disadvantaged backgrounds interested in academic careers in biomedical research, clinical investigation, and health services research and committed to serving as role models for students and faculty of similar background

Details: http://www.rwjf.org/en/grants/calls-for-proposals/2014/harold-amos-medical-faculty-development-program--amfdp-.html

Contact: Nina Ardery, Deputy director: (317) 278-0500; amfdp@indiana.edu

M 24

C A M P

Prize/Award: Strategic research agreement funding of up to $250,000 per year for up to two years for the study of modi“cations of pancreatic beta cell proteins in the pathogenesis, diagnosis, prevention, and treatment of human type 1 diabetes; multi-center collaborative projects will be considered for variable budgets

Eligibility: Applicants holding an M.D., D.M.D., D.V.M., Ph.D., or equivalent academic degree and a faculty position or equivalent at a college, university, medical school, for-pro“t research based organization, or other comparable institution

Details: http://cdn.jdrf.org/wp-content/uploads/2012/12/PTM_RFA_v6.pdf

Contact: Jessica Dunne, Ph.D.: (212) 479-7595; jdunne@jdrf.org



BD Horizon Brilliant Ultraviolet reagents open a new world of choice and productivity for scientists who use multicolor ”ow cytometry in their research. By adding the ultraviolet range to panel design,